KALA BIO, Inc.
KALAHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframeKALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United. The company carries a $9.8M market cap, placing it firmly in the micro-cap category. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment.
Market Cap
$9.8M
Beta
-2.29
P/E (TTM)
—
P/E (Fwd)
-0.08
EPS (TTM)
$-9.39
EPS (Fwd)
$-6.67
ROE
-345.3%
ROA
-65.4%
Cash
$7.2M
Total Debt
$0
Free CF
-$18.4M
52W Change
-99.9%
Annual Financials
Cash vs Debt
Where KALA stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, KALA finished 92.74% below its 150-day moving average ($7.16) and 96.28% below its 200-day moving average ($13.96). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is KALA overbought or oversold?
At the September 3, 2026 close, KALA's RSI(14) was 9.8, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
KALA BIO, Inc. reports $7.2M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$18.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -345.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $3.9M (2022) to $0 (2025), a 100% decline worth watching.
KALA's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for KALA BIO, Inc. and its sector.